Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Maze Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 75 | 1 | 94 | +20 |
| Shares | 38.8M | 30.2K | 43.0M | +4.16M (+10.7%) |
| Value | $476.7M | $371.0K | $1.11B | +$637.9M (+133.9%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held Maze Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (3)
Institutions that held Maze Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Ghisallo Capital Management LLC | 30,000 | $368.1K |
| Engineers Gate Manager LP | 10,212 | $125.3K |
| IFP Advisors, Inc | 3 | $37 |
Not filed for Q3 2025 yet (1)
Institutions that held Maze Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Congress Wealth Management LLC | 30,235 | $371.0K |